

General Information

Name: PD Dr. rer. nat. Daniel Mertens
Date of Birth: 24.11.1969
Gender: Male
Address: Department of Internal Medicine III, Ulm University
Albert-Einstein-Allee 23, 89081 Ulm, Germany
Phone: +49 731 500 45870
E-Mail: daniel.mertens@uniklinik-ulm.de
Current Position: Group leader
Head, Cooperation Unit "Mechanisms of Leukemogenesis"

University Education

1995-1996 Diploma in Developmental Genetics, Tübingen
1990-1994 Biochemistry at the Eberhard-Karls University, Tübingen

Academic Degrees

1999-2001 Doctoral Thesis (*Promotion*), Division of Molecular Genetics, DKFZ Heidelberg, Advisor: Prof. Peter Lichter
2010 Venia Legendi (*Habilitation*), Medical Faculty, Ulm University

Professional Experience

Since 2006 Head of the Cooperation Unit "Mechanisms of Leukemogenesis", Department of Internal Medicine III, Ulm University Hospital – DKFZ Heidelberg
Since 2006 Group Leader at the DKFZ in Heidelberg
2001-2006 Post-doctoral scientist, Division of Molecular Genetics (Head: Prof. Peter Lichter), DKFZ, Heidelberg
1996-1999 Functional Analyses of the cell-cycle-associated phosphatase cdc25B using tet-inducible expression systems in cell culture, Department of Prof. Harald zur Hausen, DKFZ, Heidelberg.
1996-1996 Completion of the INRA project at the Chair for Developmental Biology, Tübingen.
1996 Gene expression analyses of *GNOM*-mutants with filter-DNA-arrays at the Laboratoire de Biologie Cellulaire (INRA), Paris

Miscellaneous

Honors:

2002 Research Award of the Franziska-Kolb-Foundation for Leukemia Research, Ulm University

Publications

1. Yosifov DY*, Idler I*, Bhattacharya N*, Reichenzeller M, Close V, Ezerina D, Scheffold A, Kugler S, Bloehdorn J, Bahlo J, Robrecht S, Eichhorst B, Fischer K, Weigel A, Busch H, Lichter P, Döhner H, Dick TP, Stilgenbauer S, Mertens D. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. **Leukemia**. 2019 Jul 12. [Epub ahead of print] *Equal contribution
2. Mallm JP, Iskar M, Ishaque N, Kugler S, Muino JM, Teif V, Klett L, Poos AM, Großmann S, Erdel F, Tavernari D, Koser SD, Schumacher S, Brors B, König R, Remondini D, Stilgenbauer S, Lichter P, Vingron M, Zapatka M, Mertens D*, Rippe K*. Linking chromatin features and transcription factor networks in CLL. **Mol Syst Biol**. 2019 May 22. [Epub ahead of print] *Equal contribution
3. Close V, Close W, Kugler SJ, Reichenzeller M, Yosifov DY, Bloehdorn J, Pan L, Tausch E, Westhoff MA, Döhner H, Stilgenbauer S, Oswald F, Mertens D. FBXW7 mutations reduce binding of

- NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. **Blood**. 2019;133(8):830-39.
4. Grasedieck, S, Mulaw M, Sperb N, Wessinger K, Rouhi A, Bommer M, Bromberg JEC, Otto M, Tumani H, von Arnim CAF, Mertens D*, Kuchenbauer F*. Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. **Neuropathol Appl Neurobiol**. 2019;45(3):318-323. *Equal contribution
 5. Landau, DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Bottcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelman J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Dohner H, Hallek M, Neuberger D, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. **Nature**. 2015;526(7574):525-30.
 6. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowicz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Dohner H, Kuppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. **Nat Genet**. 2015;48(3):253-64.
 7. Bhattacharya N, Reichenzeller M, Caudron-Herger M, Haebe S, Brady N, Diener S, Nothing M, Dohner H, Stilgenbauer S, Rippe K, Mertens D. Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF- κ B and STAT6. **Int J Cancer**. 2015;136(1):65-73.
 8. Garding A, Bhattacharya N, Claus R, Ruppel M, Tschuch C, Zucknick M, Oakes C, Fleig V, Allegra D, Caudron-Herger M, Filarsky K, Keklikoglou I, Serra L, Weichenhan D, Idler I, Benner A, Radlwimmer B, Zentgraf H, Wiemann S, Rippe K, Plass C, Döhner H, Lichter P, Stilgenbauer S, Mertens D. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia correlates with downregulation in cis of a gene cluster regulating NF- κ B. **PLoS Genetics**. 2013;9(4):e1003373.
 9. Bhattacharya N, Diener S, Idler IS, Barth TF, Rauen J, Habermann A, Zenz T, Moller P, Dohner H, Stilgenbauer S, Mertens D. Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood. **Leukemia**. 2011;25(4):722-26.
 10. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. **Nat Rev Cancer**. 2010;10(1):37-50.